Syneron Candela's Ultrashape Is Challenging Exercise To Eliminate Stubborn Fat
Thursday, February 19, 2015
Syneron Medical Ltd. (NASDAQ: ELOS), a global leader in the aesthetic medical device marketplace, launched a national advertising campaign on February 12, 2015 that promises to help achieve a "flatter tummy without the torture." The multi-channel campaign developed by leading Healthcare Advertising agency Abelson Taylor, highlights UltraShape® as a painless and viable alternative to traditional body shaping – especially for stubborn abdominal fat that is resistant to diet and exercise. Instead of completing sit-ups, the campaign highlights that consumers might drop up to two waist sizes in just three 45-minute sessions, with some visible results seen as early as two weeks.
As the first and only FDA-approved non-invasive body contouring system of its kind, UltraShape offers measurable fat reduction to the abdominal area (an average of loss of 1.3 – 2.5 inches) without the risks associated with other fat reduction procedures. Pulsed focused ultrasound energy is used to precisely and non thermally target subcutaneous fat, while keeping the surrounding tissue, blood vessels, nerves and muscles intact.
"UltraShape uses ultrasound technology that was perfected in 10 years of research and development by world leading scientists and doctors to non-invasively destruct fat without any damage to surrounding tissue," states Shimon Eckhouse, Ph.D., Chairman of the Board of Directors for Syneron Candela. "UltraShape efficiency in non-invasive fat destruction has been studied and proven in more than 13 clinical studies with more than 900 patients treated by this technology. These studies have also demonstrated the excellent safety record of the technology as well as its ability to do it with no downtime to the patient. Following the FDA clearance of the technology we are very proud to bring this new and exciting technology to US patients"
Research conducted by Syneron Candela found that 72 percent of women are dissatisfied with their abdominal area. "Non-invasive body shaping is a growth driver for Syneron Candela and the aesthetic market place," says Amit Meridor, Chief Executive Officer of Syneron Candela. "UltraShape's unique abilities make it extremely appealing to the increasing number of men and women seeking safe, quick, and painless ways to reduce suborn abdominal fat."
UltraShape targets stubborn fat that doesn't disappear with diet and exercise. Unlike liposuction, the treatment is non-surgical, which means no incisions, anesthetics or recovery time. It is painless and there is no downtime. UltraShape is an ideal 'lunch hour' treatment as patients can resume normal activities immediately after.
"Men and women go to great lengths to get toned, flat abs, submitting to the agony of extreme fitness classes, juice cleanses and crunches," says Ilan Nacasch, Chief Brand Officer at Syneron Candela. "Achieving a flatter stomach doesn't have to be torture. Our goal with UltraShape is to revolutionize the way men and women attain a flatter tummy by offering technologically advanced, non-invasive and comfortable options for rapid, visible body shaping."
To learn more about the UltraShape procedure, visit: www.ultrashape.com
About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
About Abelson Taylor
Abelson Taylor is the largest independent healthcare advertising agency in the world, serving pharmaceutical, biotech and health-and-wellness companies globally. Since 1981, the agency has remained singularly focused on brands that help people live healthier lives. AbelsonTaylor is 100 percent focused on and passionate about health and wellness. Clients see it in the brands we represent and feel it in the environment we create. AbelsonTaylor has built a reputation as the most creative agency that creates brand experiences in broadcast, print, and digital. To learn more visit abelsontaylor.com and follow on Twitter and Facebook.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
 Syneron data on file
 Syneron data on file